T Cell Therapy Treats Atopic Dermatitis
A Lancet comment published August 21, 2026, discusses rezpegaldesleukin, a novel therapy designed to expand regulatory T cells for treating
A new therapeutic approach targeting regulatory T cells shows promise for treating moderate-to-severe atopic dermatitis. This is according to a comment published in The Lancet on August 21, 2026, which analyzes final results from the 16-week induction period of the REZOLVE-AD phase 2b trial for the drug rezpegaldesleukin.
Atopic dermatitis remains a highly burdensome inflammatory skin disease globally. It substantially affects quality of life, sleep, mental health, and healthcare use. The Global Burden of Disease Study analyses rank it among the leading skin diseases by disability-adjusted life-years.
Treatment has changed markedly over the past decade. Biologics targeting type 2 inflammation and oral Janus kinase (JAK) inhibitors have expanded options. Yet, a relevant proportion of patients with moderate-to-severe disease still lack durable control. Many lose response or discontinue due to tolerability or safety concerns.
The Rationale for a New Target
The comment, authored by Fernando Valenzuela and Maximiliano Davalos Munoz, argues that regulatory T cells represent a compelling therapeutic target. These cells are crucial for maintaining immune tolerance. Their functional impairment is a hallmark of allergic diseases like atopic dermatitis.
Expanding this cell population could restore immune balance. The authors cite previous research showing that interleukin-2 (IL-2) is critical for regulatory T cell survival and function. However, its use has been limited because it also stimulates pro-inflammatory cells.
Rezpegaldesleukin's Proposed Mechanism
Rezpegaldesleukin is a PEGylated form of human IL-2. It is engineered for selective activity. The drug is designed to have a preferential binding affinity for the high-affinity IL-2 receptor. This receptor is highly expressed on regulatory T cells.
This design aims to selectively expand and activate regulatory T cells. The goal is to suppress the pathological inflammation in atopic dermatitis without broadly activating other immune cells. The approach is based on earlier work with a human anti-IL-2 antibody that was shown to potentiate regulatory T cells through a structure-based mechanism.
Insights from the REZOLVE-AD Trial
The comment is framed around the recently published REZOLVE-AD trial results. That study was an international, double-blind, placebo-controlled, randomised phase 2b trial. It evaluated rezpegaldesleukin for moderate-to-severe atopic dermatitis.
The authors position this development within the ongoing search for targeted therapeutics. They reference the concept of atopic dermatitis endotypes and the need for treatments matching specific disease pathways. The expanding therapeutic pipeline for this complex disease continues to evolve.
Current systemic treatments are guided by frameworks like the European guideline on atopic eczema. Living systematic reviews and network meta-analyses continually update the evidence landscape. The arrival of a therapy working through regulatory T cell expansion adds a new dimension.
Previous breakthroughs included biologics like dupilumab and an anti-OX40 antibody. Each targets different components of the dysregulated immune response. The potential of rezpegaldesleukin lies in its upstream approach of boosting the body's natural regulatory mechanisms.
The final results from the 16-week induction period of the REZOLVE-AD study provide the first clinical evidence for this strategy in atopic dermatitis.
